Fideuram Asset Management Ireland dac Takes Position in Boston Scientific Corporation $BSX

Fideuram Asset Management Ireland dac acquired a new stake in Boston Scientific Corporation (NYSE:BSX) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 30,308 shares of the medical equipment provider’s stock, valued at approximately $3,118,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. National Pension Service increased its position in shares of Boston Scientific by 8.6% in the fourth quarter. National Pension Service now owns 3,761,615 shares of the medical equipment provider’s stock valued at $358,670,000 after buying an additional 296,409 shares in the last quarter. Mitsubishi UFJ Morgan Stanley Securities Co. Ltd. purchased a new stake in shares of Boston Scientific in the fourth quarter valued at approximately $226,000. SBI Okasan Asset Management Co.Ltd. purchased a new stake in shares of Boston Scientific in the fourth quarter valued at approximately $1,842,000. United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund purchased a new stake in shares of Boston Scientific in the fourth quarter valued at approximately $10,287,000. Finally, Northwestern Mutual Wealth Management Co. increased its position in shares of Boston Scientific by 9.5% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 735,852 shares of the medical equipment provider’s stock valued at $70,164,000 after buying an additional 63,773 shares in the last quarter. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, Director Cheryl Pegus acquired 1,770 shares of the stock in a transaction on Wednesday, May 20th. The shares were bought at an average price of $56.49 per share, with a total value of $99,987.30. Following the completion of the purchase, the director owned 1,770 shares of the company’s stock, valued at approximately $99,987.30. This represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director David C. Habiger acquired 2,250 shares of the stock in a transaction on Wednesday, May 20th. The shares were bought at an average cost of $55.92 per share, for a total transaction of $125,820.00. Following the purchase, the director directly owned 13,878 shares of the company’s stock, valued at $776,057.76. The trade was a 19.35% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders have purchased 9,800 shares of company stock valued at $554,012. Insiders own 0.34% of the company’s stock.

Boston Scientific Stock Performance

NYSE BSX opened at $49.12 on Friday. The stock’s fifty day moving average is $60.69 and its two-hundred day moving average is $78.84. The firm has a market capitalization of $73.01 billion, a P/E ratio of 20.55, a price-to-earnings-growth ratio of 0.93 and a beta of 0.62. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. Boston Scientific Corporation has a fifty-two week low of $48.41 and a fifty-two week high of $109.50.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. The company had revenue of $5.20 billion for the quarter, compared to analyst estimates of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The firm’s revenue for the quarter was up 11.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, research analysts anticipate that Boston Scientific Corporation will post 3.37 earnings per share for the current year.

Boston Scientific announced that its board has approved a share buyback plan on Monday, May 18th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical equipment provider to buy up to 6.4% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s leadership believes its shares are undervalued.

Analyst Ratings Changes

A number of brokerages have recently issued reports on BSX. Needham & Company LLC reaffirmed a “buy” rating and issued a $77.00 price target on shares of Boston Scientific in a research note on Monday, May 18th. National Bank Financial set a $115.00 price target on Boston Scientific in a research note on Monday, February 2nd. Truist Financial lowered their price target on Boston Scientific from $90.00 to $85.00 and set a “buy” rating on the stock in a research note on Thursday, April 23rd. Canaccord Genuity Group lowered their price target on Boston Scientific from $109.00 to $71.00 and set a “buy” rating on the stock in a research note on Thursday, April 23rd. Finally, JPMorgan Chase & Co. lowered their price target on Boston Scientific from $135.00 to $100.00 and set an “overweight” rating on the stock in a research note on Thursday, February 5th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $87.46.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific advanced several clinical programs, including updates on its FARAPULSE pulsed-field ablation study and a diabetic neuropathy trial that is nearing a key data milestone, which could support future product growth. Boston Scientific Advances FARAPULSE PFA Study in Atrial Fibrillation
• Positive Sentiment: Unusual options activity showed heavy call buying in BSX, suggesting some traders are positioning for a rebound.
• Neutral Sentiment: Wall Street brokerage consensus still leans bullish overall, with the stock holding a “Moderate Buy” rating from analysts.
• Neutral Sentiment: Boston Scientific continues to work on its device pipeline and capital deployment strategy, which may help offset current franchise weakness over time. Boston Scientific (BSX) Device Succeeds in Over 93% of Patients in Its Pivotal Trial
• Negative Sentiment: Wells Fargo downgraded Boston Scientific to Equal Weight from Overweight, citing uncertainty around the EP business and the WATCHMAN franchise. Wells Fargo cuts Boston Scientific to ’Equal Weight’ on Watchman slowdown
• Negative Sentiment: Management’s reduced 2026 organic growth outlook and comments about slower WATCHMAN procedures and competitive pressure in electrophysiology were the main catalysts behind the stock’s decline. Boston Scientific shares fall 10% on Watchman weakness, competitive pressures

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.